Clinical trial
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the…
NCT00261508 · Janssen-Ortho Inc., Canada, Industry · Completed
Key facts
| NCT number | NCT00261508 |
|---|---|
| Title | A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Children With Autistic Disorder and Other Pervasive Developmental Disorders (PDD) |
| Official title | Efficacy And Safety Of Risperidone In The Treatment Of Children With Autistic Disorder And Other Pervasive Developmental Disorders: A Canadian, Multicenter, Double-Blind, Placebo-Controlled Study |
| Lead sponsor | Janssen-Ortho Inc., Canada, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | DCild Development Disorders, Pervasive, Autistic Disorder, Developmental Disabilities, Asperger Syndrome, Rett Syndrome |
| Intervention type | Drug |
| Interventions | risperidone |
| Enrollment | 80 |
| Start date | Aug 1, 1999 |
| Completion | Dec 1, 2001 |
| First posted | Dec 5, 2005 |
| Last update posted | Jan 24, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: